SecBot SecBot
SECBOTREPLAY Home › Report › DRTS

DRTS · The FDA has approved an IDE supplement expanding Alpha Tau's IMPACT…

Alpha Tau Medical Ltd. · PRESS-RELEASE filed Apr 23, 2026 at 09:02 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Apr 23, 2026 at 09:02 ET

The FDA has approved an IDE supplement expanding Alpha Tau's IMPACT pilot trial for pancreatic cancer to include 10 additional patients receiving gemcitabine/nab-paclitaxel chemotherapy, increasing total enrollment from 30 to 40. The expansion allows evaluation of Alpha DaRT in combination with both major first-line chemotherapies, broadening the potential development path for this investigational therapy in a high-unmet-need population.

  • FDA approved an IDE supplement to expand the IMPACT trial from 30 to 40 patients
  • Expansion includes 10 new patients receiving gemcitabine/nab-paclitaxel alongside Alpha DaRT
  • Trial now covers both major first-line chemotherapies: mFOLFIRINOX and gemcitabine/nab-paclitaxel
  • Patient recruitment now expected to complete in Q3 2026, delayed from Q2 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access